New
-
New pulmonary embolism treatments offer patients freedom from needles
Treatments for pulmonary embolisms (PE) will evolve to better suit patient needs and enhance their quality of life, according to a report by GlobalData.
New | 24 May 2012
-
Technology gains renewing interest in needle arrays as drug delivery devices
Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered.
New | 12 April 2012
-
Espicom predicts new novel approaches to the treatment of cancer will be launched by 2018
According to an Espicom report, Targeted Cancer D: The launch landscape to 2018,the global cancer market could be set for rapid growth in key sectors, driven by increasingly un-met clinical need and the introduction of new drugs which effectively target new pathways.
New | 29 March 2012
-
US FDA clears investigational new drug application, phase 2B trial for Immuron’s NASH/Fatty liver therapeutic
Immuron announced that the United States Food and Drug Administration (US FDA) had cleared an Investigational New Drug (IND) submission to commence a Phase 2b clinical trial of its bovine colostrum-derived therapeutic (IMM-124E) for the treatment of Non-Alcoholic Steatohepatitis (NASH) and Fatty Liver.
New | 06 March 2012
-
DOCS continues expansion with four new offices in Europe
ICON announced that its resourcing division, DOCS, has expanded in Europe by opening four new offices: in Milan, Italy; Budapest, Hungary; Brussels, Belgium and Berlin, Germany. This latest expansion brings the total number of DOCS offices in Europe to 22.
New | 03 February 2012
-
Molecular Profiles invests in new facility to increase manufacturing capabilities for clinical trials
Molecular Profiles, a leading specialist contract research and manufacturing organization, announces the commencement of construction of a new manufacturing facility. This £9 million investment will allow Molecular Profiles to expand its current manufacturing capabilities while strengthening its existing expertise in the drug development field.
New | 19 January 2012
-
Werum appoints head of new central business unit
Richard Nagorny is in charge of the newly established central business unit Shared Service Center at Werum Software & Systems AG. He is responsible for finances, controlling, procurement, human resources, internal IT, and Infrastructure. He reports directly to the executive board. Nagorny held the CFO position at the pharmaceutical group AstraZeneca Germany in Wedel before joining Werum.
New | 28 November 2011
-
Plexxikon novel agents aim to address cancer treatment in new ways
Plexxikon announced scientific findings from two key programs in its oncology pipeline. First, findings from preclinical studies showed that treatment with a novel oral agent, PLX3397, re-programmed the tumor microenvironment, supporting further development of this single agent treatment for certain cancers and malignancies such as prostate cancer. In another presentation, Plexxikon researchers characterized the discovery of next generation BRAF inhibitors based on a preclinical model showing that these new inhibitors avoided the drug-induced skin lesions (cutaneous squamous cell carcinoma) observed with other BRAF inhibitors.
New | 21 November 2011
-
New data presented on phase 3 trial Of ELIQUIS (apixaban) in the prevention of venous thromboembolism in patients with acute medical illness
Bristol-Myers Squibb and Pfizer announced the results of the Phase 3 ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial, which evaluated apixaban versus enoxaparin in acutely ill medical patients, did not meet the primary efficacy outcome of superiority to enoxaparin for the endpoint of venous thromboembolism (VTE) and VTE-related death at day 30.
New | 15 November 2011
-
AMRI appoints new President, India Operations
Subramanyam Maddala assumes leadership for AMRI’s Indian API manufacturing operations as well as responsibility for AMRI facility operations in Hyderabad and Aurangabad, India.
New | 14 October 2011
